| HOME >> BIOLOGY >> TECHNOLOGY |
Consolidated revenues for the nine month period ended August 31, 2008 were approximately $13.1 million as compared to approximately $13.2 million for the nine months ended August 31, 2007. The Company reported a net loss for the nine months ended August 31, 2008 of approximately ($792,000), or ($0.07) per basic common share, compared to a net loss of approximately ($3,338,000), or ($0.29) per basic common share, for the nine months ended August 31, 2007. The 76% decrease year over year in the net loss for the nine months ended August 31, 2008 is primarily the result of a 22% decrease in marketing, general and administrative expenses. In addition, research and development expenses were approximately $162,000 for the nine months ended August 31, 2008, a decrease of approximately 66% in comparison to the same period in 2008.
The Company recognized approximately $758,000 in licensee income for
the nine months ended August 31, 2008, compared to approximately $779,000
for the 2007 period. Licensee income for the nine months ended August 31,
2008 consisted of the first installment of $100,000, from the sale of the
C'elle license and royalty agreement with Lifecell International Private,
Ltd. and the first installment of $100,000 from the sale of the U-Cord
license and royalty agreement with Cryo-Cell de Venezuela, as described
above. The remaining $562,000 is royalty income earned on subsequent
processing and storage of specimens in geographi
'/>"/>
| SOURCE Cryo-Cell International, Inc. Copyright©2008 PR Newswire. All rights reserved |